In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication
A novel coronavirus, named SARS-CoV-2, emerged in 2019 in China and rapidly spread
worldwide. As no approved therapeutics exists to treat COVID-19, the disease associated to …
worldwide. As no approved therapeutics exists to treat COVID-19, the disease associated to …
Drug repurposing screen for compounds inhibiting the cytopathic effect of SARS-CoV-2
CZ Chen, P Shinn, Z Itkin, RT Eastman… - Frontiers in …, 2021 - frontiersin.org
Drug repurposing is a rapid approach to identify therapeutics for the treatment of emerging
infectious diseases such as COVID-19. To address the urgent need for treatment options, we …
infectious diseases such as COVID-19. To address the urgent need for treatment options, we …
Discovery of potent SARS-CoV-2 inhibitors from approved antiviral drugs via docking and virtual screening
Background: Coronavirus Disease 2019 (COVID-19) pandemic continues to threaten
patients, societies and healthcare systems around the world. There is an urgent need to …
patients, societies and healthcare systems around the world. There is an urgent need to …
Identification of potent and safe antiviral therapeutic candidates against SARS-CoV-2
X Xiao, C Wang, D Chang, Y Wang, X Dong… - Frontiers in …, 2020 - frontiersin.org
COVID-19 pandemic has infected millions of people with mortality exceeding> 1 million.
There is an urgent need to find therapeutic agents that can help clear the virus to prevent …
There is an urgent need to find therapeutic agents that can help clear the virus to prevent …
[HTML][HTML] Identification of inhibitors of SARS-CoV-2 in-vitro cellular toxicity in human (Caco-2) cells using a large scale drug repurposing collection
To identify possible candidates for progression towards clinical studies against SARS-CoV-
2, we screened a well-defined collection of 5632 compounds including 3488 compounds …
2, we screened a well-defined collection of 5632 compounds including 3488 compounds …
Revisiting potential druggable targets against SARS‐CoV‐2 and repurposing therapeutics under preclinical study and clinical trials: A comprehensive review
Abstract Coronavirus disease‐19 (COVID‐19), caused by severe acute respiratory
syndrome coronavirus 2 (SARS‐CoV‐2), is one of the most contagious diseases in human …
syndrome coronavirus 2 (SARS‐CoV‐2), is one of the most contagious diseases in human …
[HTML][HTML] Drug discovery strategies for SARS-CoV-2
Coronavirus disease 2019 (COVID-19) is a novel disease caused by the severe acute
respiratory syndrome coronavirus (SARS-CoV)-2 virus that was first detected in December of …
respiratory syndrome coronavirus (SARS-CoV)-2 virus that was first detected in December of …
Drugs repurposed for COVID-19 by virtual screening of 6,218 drugs and cell-based assay
WD Jang, S Jeon, S Kim… - Proceedings of the …, 2021 - National Acad Sciences
The COVID-19 pandemic caused by SARS-CoV-2 is an unprecedentedly significant health
threat, prompting the need for rapidly developing antiviral drugs for the treatment. Drug …
threat, prompting the need for rapidly developing antiviral drugs for the treatment. Drug …
Drug repurposing for COVID-19: A review and a novel strategy to identify new targets and potential drug candidates
L Rodrigues, R Bento Cunha, T Vassilevskaia… - Molecules, 2022 - mdpi.com
In December 2019, the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2), the causative agent of coronavirus disease 2019 (COVID-19) was first identified in the …
2), the causative agent of coronavirus disease 2019 (COVID-19) was first identified in the …
A SARS-CoV-2 cytopathicity dataset generated by high-content screening of a large drug repurposing collection
SARS-CoV-2 is a novel coronavirus responsible for the COVID-19 pandemic, in which acute
respiratory infections are associated with high socio-economic burden. We applied high …
respiratory infections are associated with high socio-economic burden. We applied high …